Platelet-rich plasma effective remedy for dry eye

Article

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Jorge Alio and colleagues from the Instituto Oftalmologico de Alicante and the Universidad Migul Hernandez, Alicante, Spain, treated 18 consecutive dry eye patients with topical PRP. The researchers were looking for the disappearance of subjective symptoms, increases in best corrected visual acuity (BCVA), tear meniscus, tear break-up time and decreases in inflammation and fluorescein staining. Improvements in impression cytology were also measured.

At one-month follow-up, 89% of subjects demonstrated a significant improvement in symptoms and 28% improved by at least one line of BCVA. A significant improvement in lachrymal meniscus and conjunctival hyperaemia, and a decrease or disappearance of corneal fluorescein staining was observed. Meanwhile, impression cytology revealed a significant increase in conjunctival goblet cells.

The authors of the study conclude that autologous PRP is a very effective treatment for severe dry eye symptoms.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.